Researchers at the Wake Forest Institute for Regenerative Medicine are examining possible treatments that utilize a patient's cells to deliver "long-lasting Factor VIII" to treat Hemophilia A. In a study done by the institute, they investigated a range of cell types: fluid-derived, adult cells, and neonatal. The researchers inspected these cells' use to deliver the Factor medication. The institute's researchers also evaluated which cells were capable of producing fully functional Factor IVV protein. These scientists hope this drives research in the future as they "look forward to seeing this work progress,” says the director Anthony Atala, MD. Anthony also says the "data lay the groundwork for future studies to gain a better understanding of the cellular and molecular factors, and to harness the pathways to drive high level Factor VIII expression in other clinically viable cell types.” The Hemophilia Community is rooting for Anthony Atala, and his team.
top of page
bottom of page
Comments